Intellectual Property News & Topics - Secerna LLP

WAKIX (1)

A to Z: Drugs in Highlight: W is for WAKIX®

News A to Z Feature 08/05/2025

Our A to Z series highlights WAKIX® (from Bioprojet Pharma) which is used to treat narcolepsy in adults, adolescents and children from 6 years of age. The active substance in WAKIX® is pitolisant. Pitolisant works by blocking histamine from attaching to the histamine H3 receptor on nerve cells.

Read more

The Art And Science Of Fireworks A Celebration In The Sky

Industry news, News 31/10/2024

Patents and Innovations in Fireworks: A Celebration in the Sky

Secerna Website Images 2023 (19)

Industry news, News 29/10/2024

Halloween Patents: How IP Law Governs the Spookiest Holiday of the Year

T251018 – Exceptions To Patentability And Novelty Of Naturally Occurring Substances

Industry news, News 23/10/2024

T2510/18 – Exceptions to Patentability and Novelty of Naturally Occurring Substances

Copyright European Union. (1)

European, Industry news, News 22/10/2024

EU Council Approves Modernised Design Protection Package

AgriTech and Intellectual Property

Industry news, News 17/10/2024

AgriTech and Intellectual Property

Secerna Interior Shots September 2024 002

Industry news, News, Team news 08/10/2024

Secerna LLP Strengthens Chemistry & Pharmaceutical Team with New Patent Attorney

Mpox: Emerging Challenges and Pharmaceutical Innovations in the Face of a Global Health Crisis (Main)

Industry news, News 07/10/2024

Mpox: Emerging Challenges and Pharmaceutical Innovations in the Face of a Global Health Crisis

Navigating Employee Inventor Rights

Industry news, News 30/09/2024

Navigating Employee Inventor Rights

Secerna Highlights IP Importance on "Why Small Business Matters" Podcast

Events, Industry news, News 25/09/2024

Secerna Highlights IP Importance on "Why Small Business Matters" Podcast

3 4 5 6 7 8 9 10 11 12 13